David C. Seldin

David C. Seldin

Auto-generated profile, based on publicly available information

David C. Seldin

Section of Hematology-Oncology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
DLDavid Y. Lou
David Y. Lou
IDIsabel Dominguez
Isabel Dominguez
PTPaul Toselli
Paul Toselli
ELEsther Landesman-Bollag
Esther Landesman-Bollag
COConor O'BRien
Conor O'BRien
DSDavid C. Seldin
David C. Seldin
Protein kinase CK2 (formerly casein kinase II) is a highly conserved and ubiquitous serine/threonine kinase that is composed of two catalytic subunits (CK2alpha and/or CK2alpha') and two CK2beta regulatory subunits. CK2 has many substrates in cells, and key roles in yeast cell physiology have been uncovered by introducing subunit mutations. Gene-targeting experiments have demonstrated that in mice, the CK2beta gene is required for early embryonic development, while the CK2alpha' subunit appears to be essential only for normal spermatogenesis. We have used homologous recombination to disrupt the CK2alpha gene in the mouse germ line. Embryos lacking CK2alpha have a marked reduction in CK2 activity in spite of the presence of the CK2alpha' subunit. CK2alpha(-/-) embryos die in mid-gestation, with abnormalities including open neural tubes and reductions in the branchial arches. Defects in the formation of the heart lead to hydrops fetalis and are likely the cause of embryonic lethality. Thus, CK2alpha appears to play an essential and uncompensated role in mammalian development.

24 April 2009 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
IDI. Dominguez
I. Dominguez
GSG. E. Sonenshein
G. E. Sonenshein
DSD. C. Seldin
D. C. Seldin

16 March 2016 in BMC Biology
Verified
Journal Article
Open access
PDF file
ESElizabeth A. Stanford
Elizabeth A. Stanford
ZWZhongyan Wang
Zhongyan Wang
ONOlga Novikov
Olga Novikov
FMFrancesca Mulas
Francesca Mulas
ELEsther Landesman-Bollag
Esther Landesman-Bollag
DSDavid Sherr
David Sherr
Self-renewing, chemoresistant breast cancer stem cells are believed to contribute significantly to cancer invasion, migration and patient relapse. Therefore, the identification of signaling pathways that regulate the acquisition of stem-like qualities is an important step towards understanding why patients relapse and towards development of novel therapeutics that specifically target cancer stem cell vulnerabilities. Recent studies identified a role for the aryl hydrocarbon receptor (AHR), an environmental carcinogen receptor implicated in cancer initiation, in normal tissue-specific stem cell self-renewal. These studies inspired the hypothesis that the AHR plays a role in the acquisition of cancer stem cell-like qualities. To test this hypothesis, AHR activity in Hs578T triple negative and SUM149 inflammatory breast cancer cells were modulated with AHR ligands, shRNA or AHR-specific inhibitors, and phenotypic, genomic and functional stem cell-associated characteristics were evaluated. The data demonstrate that (1) ALDHhigh cells express elevated levels of Ahr and Cyp1b1 and Cyp1a1, AHR-driven genes, (2) AHR knockdown reduces ALDH activity by 80 %, (3) AHR hyper-activation with several ligands, including environmental ligands, significantly increases ALDH1 activity, expression of stem cell- and invasion/migration-associated genes, and accelerates cell migration, (4) a significant correlation between Ahr or Cyp1b1 expression (as a surrogate marker for AHR activity) and expression of stem cell- and invasion/migration-associated gene sets is seen with genomic data obtained from 79 human breast cancer cell lines and over 1,850 primary human breast cancers, (5) the AHR interacts directly with Sox2, a master regulator of self-renewal; AHR ligands increase this interaction and nuclear SOX2 translocation, (6) AHR knockdown inhibits tumorsphere formation in low adherence conditions, (7) AHR inhibition blocks the rapid migration of ALDHhigh cells and reduces ALDHhigh cell chemoresistance, (8) ALDHhigh cells are highly efficient at initiating tumors in orthotopic xenografts, and (9) AHR knockdown inhibits tumor initiation and reduces tumor Aldh1a1, Sox2, and Cyp1b1 expression in vivo. These data suggest that the AHR plays an important role in development of cells with cancer stem cell-like qualities and that environmental AHR ligands may exacerbate breast cancer by enhancing expression of these properties.

15 November 2002
Verified
Journal Article
Closed access
RRRaphaëlle Romieu-Mourez
Raphaëlle Romieu-Mourez
ELEsther Landesman-Bollag
Esther Landesman-Bollag
DSDavid C Seldin
David C Seldin
GSGail E Sonenshein
Gail E Sonenshein

2 July 2008 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
DSDavid C. Seldin
David C. Seldin
DLDavid Y. Lou
David Y. Lou
PTPaul Toselli
Paul Toselli
ELEsther Landesman-Bollag
Esther Landesman-Bollag
IDIsabel Dominguez
Isabel Dominguez

4 January 2007 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
CKCynthia A. Kos
Cynthia A. Kos
JWJennifer E. Ward
Jennifer E. Ward
KMKarim Malek
Karim Malek
VSVaishali Sanchorawala
Vaishali Sanchorawala
DWDaniel G. Wright
Daniel G. Wright
DSDavid C. Seldin
David C. Seldin
Acquired loss of functional von Willebrand factor (VWF) has been termed the acquired von Willebrand syndrome (AVWS). AVWS is a rare adult‐onset bleeding diathesis that is clinically similar to congenital von Willebrand disease (VWD), and occurs with a variety of autoimmune, lymphoproliferative, or myeloproliferative disorders. We have identified four patients with AVWS in association with immunoglobulin light chain (AL) amyloidosis. These patients, lacking any pre‐existing or family history of abnormal bleeding, developed cutaneous, mucosal, or gastrointestinal bleeding in the course of their disease without deficiency of clotting factor X or other factors; the activated partial thromboplastin time (aPTT) was prolonged in three out of the four cases. Despite normal VWF antigen levels, VWF ristocetin cofactor activity (VWF:RCo) was low. Electrophoresis patterns of high molecular weight (HMW) VWF multimers were abnormal in two of the four cases. Two of the patients were treated with high‐dose intravenous melphalan followed by autologous stem cell transplantation (HDM/SCT) and achieved hematologic remission. In these two patients, the bleeding diathesis improved and the coagulation parameters normalized, confirming a causal relationship between the plasma cell dyscrasia and the AVWS. AVWS should be considered in AL amyloidosis patients with hemorrhagic diatheses and normal clotting factor levels. Am. J. Hematol., 2007.